Drug development for recurrent and refractory classical Hodgkin lymphoma

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96
   PubMed Web of Science ®Google Scholar
• Linch D C, Goldstone A H, McMillan A, Chopra R, Vaughan Hudson G, Winfield D, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054
   PubMed Web of Science ®Google Scholar
• Schmitz N, Haverkamp H, Josting A, Diehl V, Pfistner B, Carella A M, et al. Long term follow up in relapsed Hodgkin's disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. J Clin Oncol ASCO Annual Meeting Proceedings 2005; 23: 6508
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Lin T S, Avalos B R, Penza S L, Marcucci G, Elder P J, Copelan E A. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease. Bone Marrow Transplant 2002; 29: 763–767
   PubMed Web of Science ®Google Scholar
• Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone A. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European Blood and Bone Marrow Registry. J Clin Oncol 1997; 15: 1595–1600
   PubMed Web of Science ®Google Scholar
• Thomson K J, Peggs K S, Smith P, Chopra R, Cavet J, Hunter A, et al. Improved outcome following reduced intensity allogeneic transplantation in Hodgkin's lymphoma relapsing post-autologous transplantation. ASH Annu Meet Abstr 2005; 106: 657
   Google Scholar
• Sureda A, Robinson S, Canals C, Carella A M, Boogaerts M A, Caballero D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455–462
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez M A, Fiumara P, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003; 98: 310–314
   PubMed Web of Science ®Google Scholar
• Wedgwood A R, Fanale M A, Fayad L E, McLaughlin P, Hagemeister F B, Pro B, et al. Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International prognostic score (IPS) groups and in patients who have PET positive disease after 2–3 cycles of therapy. ASH Annu Meet Abstr 2007; 110: 215
   Google Scholar
• Tepler I, Schwartz G, Parker K, Charette J, Kadin M E, Woodworth T G, et al. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994; 73: 1276–1285
   PubMed Web of Science ®Google Scholar
• LeMaistre C F, Saleh M N, Kuzel T M, Foss F, Platanias L C, Schwartz G, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91: 399–405
   PubMed Web of Science ®Google Scholar
• Kreitman R J, Wilson W H, White J D, Stetler-Stevenson M, Jaffe E S, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622–1636
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig M-T, Drillich S, et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997; 89: 403–410
   PubMed Web of Science ®Google Scholar
• Schnell R, Borchmann P, Staak J O, Schindler J, Ghetie V, Vitetta E S, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 2003; 14: 729–736
   PubMed Web of Science ®Google Scholar
• Bartlett N L, Younes A, Carabasi M H, Forero A, Rosenblatt J D, Leonard J P, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008; 111: 1848–1854
   PubMed Web of Science ®Google Scholar
• Leonard J P, Rosenblatt J D, Bartlett N L, Gopal A, Younes A, Fisher D, et al. Phase II study of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent Hodgkin's disease. ASH Annu Meet Abstr 2004; 104: 2635
   Google Scholar
• Leonard J P, Younes A, Rosenblatt J D, Gopal A, Pinter-Brown L C, Bartlett N L, et al. Targeting CD30 as therapy for Hodgkin's disease. Phase II results with the monoclonal antibody SGN-30. J Clin Oncol ASCO Annual Meeting Proceedings 2005; 23: 2553, [Abstract]
   Google Scholar
• Blum K A, Johnson J L, Jung S, Cheson B D, Bartlett N L. Serious pulmonary toxicity with SGN-30 and gemcitabine, vinorelbine, and liposomal doxorubicin in patients with relapsed/refractory Hodgkin lymphoma (HL): cancer and leukemia group B (CALGB) 50502. ASH Annu Meet Abstr 2008; 112: 232
   Google Scholar
• Ansell S M, Horwitz S M, Engert A, Khan K D, Lin T, Strair R, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25: 2764–2769
   PubMed Web of Science ®Google Scholar
• Renner C, Hartmann F, Pfreundschuh M. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Cancer Immunol Immunother 1997; 45: 184–186
   PubMed Web of Science ®Google Scholar
• Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 1997; 89: 2042–2047
   PubMed Web of Science ®Google Scholar
• Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001; 7: 1873–1881
   PubMed Web of Science ®Google Scholar
• Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis L D, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002; 100: 3101–3107
   PubMed Web of Science ®Google Scholar
• Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002; 8: 1779–1786
   PubMed Web of Science ®Google Scholar
• Falini B, Flenghi L, Aversa F, Barbabietola G, Martelli M F, Comeli P, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339: 1195–1196
   PubMed Web of Science ®Google Scholar
• Younes A, Forero-Torres A, Bartlett N L, Leonard J P, Lynch C, Kennedy D A, et al. Multiple complete responses in a phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. ASH Annu Meet Abstr 2008; 112: 1006
   Google Scholar
• Younes A, Forero-Torres A, Bartlett N L, Leonard J P, Rege B, Kennedy D A, et al. Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 2008 ASCO Annual Meeting Proceedings 2008; 26: 8526, [Abstract]
   Google Scholar
• Schnell R, Dietlein M, Staak J O, Borchmann P, Schomaecker K, Fischer T, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005; 23: 4669–4678
   PubMed Web of Science ®Google Scholar
• Lenhard R E, Jr, Order S E, Spunberg J J, Asbell S O, Leibel S A. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 1985; 3: 1296–1300
   PubMed Web of Science ®Google Scholar
• Vriesendorp H, Herpst J, Germack M, Klein J, Leichner P, Loudenslager D, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end- stage Hodgkin's disease, including Radiation Therapy Oncology Group 87- 01. J Clin Oncol 1991; 9: 918–928
   PubMed Web of Science ®Google Scholar
• Decaudin D, Levy R, Lokiec F, Madar O, Brossel R, Morschhauser F, et al. Radioimmunotherapy (RIT) of refractory or relapsed Hodgkin's lymphoma (HL) with 90-Yttrium-labelled antiferritin antibody. ASH Annu Meet Abstr 2007; 110: 4473
   Google Scholar
• Vriesendorp H M, Quadri S M, Wyllie C T, Lai J, Borchardt P E, Harris L, et al. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res 1999; 5: 3324s–3329s
   Google Scholar
• Herpst J, Klein J, Leichner P, Quadri S, Vriesendorp H. Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. J Clin Oncol 1995; 13: 2394–2400
   PubMed Web of Science ®Google Scholar
• Cerveny C G, Law C L, McCormick R S, Lenox J S, Hamblett K J, Westendorf L E, et al. Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia 2005; 19: 1648–1655
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Gattei V, Aldinucci D, Degan M, De Paoli P, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780–789
   PubMed Web of Science ®Google Scholar
• Murray P G, Oates J, Reynolds G M, Crocker J, Young L S. Expression of B7 (CD80) and CD40 antigens and the CD40 ligand in Hodgkin's disease is independent of latent Epstein-Barr virus infection. Clin Mol Pathol 1995; 48: M105–M108
   Google Scholar
• Wahl A F, Klussman K, Thompson J D, Chen J H, Francisco L V, Risdon G, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002; 62: 3736–3742
   PubMed Web of Science ®Google Scholar
• Cerveny C G, Law C-L, McCormick R S, Lenox J S, Hamblett K J, Westendorf L E, et al. The anti-CD30 monoclonal antibody SGN-30 inhibits Hodgkins disease growth and sensitizes cells to established chemotherapeutics. ASH Annu Meet Abstr 2004; 104: 2639
   Google Scholar
• Borchmann P, Treml J F, Hansen H, Gottstein C, Schnell R, Staak O, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003; 102: 3737–3742
   PubMed Web of Science ®Google Scholar
• Heuck F, Ellermann J, Borchmann P, Rothe A, Hansen H, Engert A, et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. J Immunother 2004; 27: 347–353
   PubMed Web of Science ®Google Scholar
• Boll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, et al. The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood 2005; 106: 1839–1842
   PubMed Web of Science ®Google Scholar
• Pogge E, Boell B, Tawadros S, Reiners K, Borchmann P, Hansen H, et al. The human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib induced apoptosis. ASH Annu Meet Abstr 2004; 104: 3295
   Google Scholar
• Hammond P W, Vafa O, Jacinto J, Vielmetter J, Karki S, Yoder S, et al. A humanized anti-CD30 monoclonal antibody, XmAb2513, with enhanced in vitro potency against CD30-positive lymphomas mediated by high affinity Fc-receptor binding. ASH Annu Meet Abstr 2005; 106: 1470
   Google Scholar
• Available at: http://clinicaltrials.gov. [Internet]; accessed 15 January 2009
   Google Scholar
• Jones R J, Lin L, Gocke C, Hensley K, Siedner M, Barber J P, et al. Clonotypic B cells circulate in Hodgkin's lymphoma (HL). ASH Annu Meet Abstr 2006; 108: 470
   Google Scholar
• Long L, Patawaran M, Tong X, Kantak S, Aukerman S L, Pryer N, et al. Efficacy of an antagonistic anti-CD40 monoclonal antibody, HCD122 (CHIR-12.12), in preclinical models of human non-Hodgkin's lymphoma and Hodgkin's disease. Blood (ASH Annu Meet Abstr) 2006; 108: 230, [Abstract]
   Google Scholar
• Law C L, Gordon K A, Collier J, Klussman K, McEarchern J A, Cerveny C G, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005; 65: 8331–8338
   PubMed Web of Science ®Google Scholar
• Law C-L, McEarchern J A, Cerveny C G, Smith L M, Nesterova A, Gordon K A, et al. The humanized anti-CD40 monoclonal antibody SGN-40 targets Hodgkin's disease cells through multiple mechanisms. ASH Annu Meet Abstr 2005; 106: 1476
   Google Scholar
• Forero-Torres A, Furman R R, Rosenblatt J D, Younes A, Harrop K, Drachman J G, et al. A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): results of a phase I study. J Clin Oncol 2006 ASCO Annual Meeting Proceedings 2006; 24: 7534, [Abstract]
   Google Scholar
• Leonard J P, Friedberg J W, Younes A, Fisher D, Gordon L I, Moore J, et al. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007; 18: 1216–1223
   PubMed Web of Science ®Google Scholar
• Vooijs W C, Otten H G, van Vliet M, van Dijk A J, de Weger R A, de Boer M, et al. B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease. Br J Cancer 1997; 76: 1163–1169
   PubMed Web of Science ®Google Scholar
• Francisco J A, Cerveny C G, Meyer D L, Mixan B J, Klussman K, Chace D F, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102: 1458–1465
   PubMed Web of Science ®Google Scholar
• Hamblett K J, Barton J, Cerveny C G, Andreyka J B, Kissler K M, Okeley N M, et al. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies. ASH Annu Meet Abstr 2005; 106: 610
   Google Scholar
• Menzel C, Schirrmann T, Konthur Z, Jostock T, Dubel S. Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood 2008; 111: 3830–3837
   PubMed Web of Science ®Google Scholar
• Bierman P, Vose J, Leichner P, Quadri S, Armitage J, Klein J, et al. Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol 1993; 11: 698–703
   PubMed Web of Science ®Google Scholar
• O'Mahony D, Janik J, Carrasquillo J, Seam P, Fiorillo J, Stewart D, et al. Yttrium-90 radiolabeled humanized monoclonal antibody to CD25 in refractory and relapsed Hodgkin's lymphoma. ASH Annu Meet Abstr 2008; 112: 231
   Google Scholar
• Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943–953
   PubMed Web of Science ®Google Scholar
• Zheng B, Georgakis G V, Li Y, Bharti A, McConkey D, Aggarwal B B, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004; 10: 3207–3215
   PubMed Web of Science ®Google Scholar
• Younes A, Pro B, Romaguera J, Dang N. Safety and efficacy of Bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease. ASH Annu Meet Abstr 2004; 104: 2638
   Google Scholar
• Blum K A, Johnson J L, Niedzwiecki D, Canellos G P, Cheson B D, Bartlett N L. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. Leuk Lymphoma 2007; 48: 1313–1319
   PubMed Web of Science ®Google Scholar
• Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Nickelsen M, et al. Bortezomib is not active in patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study. ASH Annu Meet Abstr 2006; 108: 2477
   Google Scholar
• Friedberg J W, Kelly J, Voci S, Marquis D, Rich L, Rossi R, et al. Bortezomib and gemcitabine in relapsed Hodgkin lymphoma (HL). ASH Annu Meet Abstr 2007; 110: 2325
   Google Scholar
• Fanale M, Fayad L, Pro B, Samaniego F, Zachariah G, Nunez C, et al. A phase I study of Bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma. ASH Annu Meet Abstr 2008; 112: 3048
   Google Scholar
• Kuruvilla J, Song K, Mollee P, Panzarella T, McCrae J, Nagy T, et al. A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 2006; 11: 25–29
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A A, Cheson B D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544–1552
   PubMed Web of Science ®Google Scholar
• Fehniger T, Larson S, Trinkaus K, Siegel M, DiPersio J, Cashen A, et al. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma (cHL): preliminary results. ASH Annu Meet Abstr 2008; 112: 2595
   Google Scholar
• Kuruvilla J, Taylor D, Wang L, Blattler C, Keating A, Crump M. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. ASH Annu Meet Abstr 2008; 112: 3052
   Google Scholar
• Georgakis G V, Yazbeck V Y, Li Y, Younes A. The histone deacetylase inhibitor vorinostat (SAHA) induces apoptosis and cell cycle arrest in Hodgkin lymphoma (HL) cell lines by altering several survival signaling pathways and synergizes with doxorubicin, gemcitabine and bortezomib. ASH Annu Meet Abstr 2006; 108: 2260
   Google Scholar
• Kirschbaum M H, Goldman B H, Zain J M, Cook J R, Rimsza L M, Forman S J, et al. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517. ASH Annu Meet Abstr 2007; 110: 2574
   Google Scholar
• Younes A, Pro B, Fanale M, McLaughlin P, Neelapu S, Fayad L, et al. Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL). ASH Annu Meet Abstr 2007; 110: 2566
   Google Scholar
• Bociek R G, Kuruvilla J, Pro B, Wedgwood A, Li Z, Drouin M, et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL). J Clin Oncol 2008 ASCO Annual Meeting Proceedings 2008; 26: 8507, [Abstract]
   Google Scholar
• Viviani S, Bonfante V, Fasola C, Valagussa P, Gianni A M. Phase II study of the histone-deacetylase inhibitor ITF2357 in relapsed/refractory Hodgkin's lymphoma patients. J Clin Oncol 2008 ASCO Annual Meeting Proceedings 2008; 26: 8532, [Abstract]
   Google Scholar
• Carlo-Stella C, Guidetti A, Viviani S, Bonfante V, Valagussa P, Marchiano A, et al. Phase II trial of combination of the histone deacetylase inhibitor ITF2357 and meclorethamine demonstrates clinical activity and safety in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL). ASH Annu Meet Abstr 2008; 112: 2586
   Google Scholar
• Ottmann O G, Spencer A, Prince H M, Bhalla K N, Fischer T, Liu A, et al. Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. ASH Annu Meet Abstr 2008; 112: 958
   Google Scholar
• Jundt F, Raetzel N, Muller C, Calkhoven C F, Kley K, Mathas S, et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein β and NF-κB activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005; 106: 1801–1807
   PubMed Web of Science ®Google Scholar
• Johnston P B, Ansell S M, Colgan J P, Habermann T M, Inwards D J, Micallef I NM, et al. mTOR inhibition for relapsed or refractory Hodgkin lymphoma: promising single agent activity with everolimus (RAD001). ASH Annu Meet Abstr 2007; 110: 2555
   Google Scholar
• Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller-Lantzsch N, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 1991; 88: 4766–4770
   PubMed Web of Science ®Google Scholar
• Gottschalk S, Edwards O L, Sili U, Huls M H, Goltsova T, Davis A R, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003; 101: 1905–1912
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G, et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003; 101: 3150–3156
   PubMed Web of Science ®Google Scholar
• Bollard C M, Aguilar L, Straathof K C, Gahn B, Huls M H, Rousseau A, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr Virus + Hodgkin's disease. J Exp Med 2004; 200: 1623–1633
   PubMed Web of Science ®Google Scholar
• Bollard C M, Huls H M, Straathof K C, Gottschalk S M, Lopez T, Chang C-C, et al. LMP2-cytotoxic T lymphocyte therapy for relapsed EBV positive lymphoma. ASH Annu Meet Abstr 2004; 104: 3276
   Google Scholar
• Bollard C M, Buza E, Huls H, Lopez T, Gottschalk S, Carrum G, et al. The use of autologous LMP2-specific cytotoxic T lymphocytes (CTL) for the treatment of relapsed EBV-positive Hodgkin disease and non-Hodgkin lymphoma. ASH Annu Meet Abstr 2005; 106: 773
   Google Scholar
• Bollard C M, Stanojevic M, Leen A M, Lopez T, Sheehan A, Carrum G, et al. Complete tumor responses in lymphoma patients who receive autologous cytotoxic T lymphocytes targeting EBV latent membrane proteins. ASH Annu Meet Abstr 2008; 112: 230
   Google Scholar